The risk of treatment-emergent mania with methylphenidate in bipolar disorder

American Journal of Psychiatry

Volumn 174, Issue 4, 2017, Pages 341-348

  Viktorin, Alexander ^a   Rydén, Eleonore ^a   Thase, Michael E ^a   Chang, Zheng ^a   Lundholm, Cecilia ^a   D'Onofrio, Brian M ^a   Almqvist, Catarina ^a   Magnusson, Patrik K E ^a   Lichtenstein, Paul ^a   Larsson, Henrik ^a   Landén, Mikael ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; LITHIUM; METHYLPHENIDATE; OLANZAPINE; QUETIAPINE; VALPROIC ACID; CENTRAL STIMULANT AGENT; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENVIRONMENTAL FACTOR; FEMALE; HEREDITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; RISK FACTOR; TREATMENT EMERGENT MANIA; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; MIDDLE AGED; REGISTER; SWEDEN;

ADOLESCENT; ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; REGISTRIES; SWEDEN; YOUNG ADULT;

EID: 85017027774     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.16040467     Document Type: Article

References (35)

1. Merikangas KR, Jin R, He JP, et al: Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry 2011; 68:241-251
2. Thase ME: Bipolar depression: diagnostic and treatment considerations. Dev Psychopathol 2006; 18:1213-1230
3. American Psychiatric Association: Diagnostic and Statistical Manual Of Mental Disorders: DSM-5, 5th ed. Washington, DC, American Psychiatric Association, 2013
4. Nierenberg AA, Miyahara S, Spencer T, et al: Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry 2005; 57:1467-1473
5. Ekman M, Granström O, Omérov S, et al: The societal cost of bipolar disorder in Sweden. Soc Psychiatry Psychiatr Epidemiol 2013; 48: 1601-1610
6. Thapar A, CooperM:Attention deficit hyperactivity disorder. Lancet 2016; 387:1240-1250.
7. Polanczyk G, deLimaMS,Horta BL, et al:Theworldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164:942-948
8. Cowen P, Harrison PJ, Burns T: Shorter Oxford Textbook of Psychiatry, 6th ed. Oxford, UK, Oxford University Press, 2012
9. Rydén E, Thase ME, Stråht D, et al: A history of childhood attentiondeficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr Scand 2009; 120:239-246
10. Kessler RC, Adler L, Barkley R, et al: The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716-723
11. Larsson H, Rydén E, Boman M, et al: Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry 2013; 203:103-106
12. Rydén E, Johansson C, Blennow K, et al: Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhoodADHD. J Neural Transm (Vienna) 2009; 116:1667-1674
13. Geddes JR, Miklowitz DJ: Treatment of bipolar disorder. Lancet 2013; 381:1672-1682
14. Arnsten AF: Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006; 31:2376-2383
15. Scheffler RM, Hinshaw SP, Modrek S, et al: The global market for ADHD medications. Health Aff (Millwood) 2007; 26:450-457
16. van den Ban E, Souverein P, Swaab H, et al: Trends in incidence and characteristics of children, adolescents, and adults initiating immediate-or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006. J Child Adolesc Psychopharmacol 2010; 20:55-61
17. Klassen LJ, Katzman MA, Chokka P: Adult ADHD and its comorbidities, with a focus on bipolar disorder. J Affect Disord 2010; 124: 1-8
18. Perugi G, Vannucchi G: The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. Expert Opin Pharmacother 2015; 16:2193-2204
19. Altshuler LL, Post RM, Leverich GS, et al: Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152:1130-1138
20. Goldberg DP: Diagnostic Issues in Depression and Generalized AnxietyDisorder.Washington,DC,AmericanPsychiatricAssociation, 2010
21. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al: The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use inbipolar disorders.AmJPsychiatry 2013; 170:1249-1262
22. Tondo L, Vázquez G, Baldessarini RJ: Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010; 121:404-414
23. Viktorin A, Lichtenstein P, Thase ME, et al: The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 2014; 171:1067-1073
24. McIntyre RS, Alsuwaidan M, Soczynska JK, et al: The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol 2013; 28:421-427
25. El-Mallakh RS: An open study of methylphenidate in bipolar depression. Bipolar Disord 2000; 2:56-59
26. Findling RL, Short EJ, McNamara NK, et al: Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:1445-1453
27. Scheffer RE, Kowatch RA, Carmody T, et al: Randomized, placebocontrolled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005; 162:58-64
28. Lichtenstein P, Halldner L, Zetterqvist J, et al: Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367:2006-2014
29. Fazel S, Zetterqvist J, Larsson H, et al: Antipsychotics, mood stabilisers, and risk of violent crime. Lancet 2014; 384:1206-1214
30. Chang Z, Lichtenstein P, Halldner L, et al: Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry 2014; 55:878-885
31. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al: The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24:659-667
32. Sellgren C, Landén M, Lichtenstein P, et al: Validity of bipolar disorder hospital discharge diagnoses: file review and multiple register linkage in Sweden. Acta Psychiatr Scand 2011; 124: 447-453
33. Ludvigsson JF, Andersson E, Ekbom A, et al: External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11:450
34. Wettermark B, Hammar N, Fored CM, et al: The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16:726-735
35. Torres I, Gómez N, Colom F, et al: Bipolar disorder with comorbid attention-deficit and hyperactivity disorder: main clinical features and clues for an accurate diagnosis. Acta Psychiatr Scand 2015; 132: 389-399